Share this Page:
Cabozantinib and sunitinib are both drugs that block the development of blood vessels to supply the tumour and are called vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). These drugs are used to treat patients with advanced kidney cancer. Clinical trials have shown that cabozantinib is better at extending survival than sunitinib, giving patients more time before their cancer progresses. It is important that this additional time before disease progression is good quality life and is not adversely affected by the side effects of treatment and/or ongoing cancer symptoms. Both quantity and quality of life are important in the development of an optimal treatment. In this study of patients with advanced untreated kidney cancer, cabozantinib provided more quality time before cancer progression compared with sunitinib.